Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicaid Waivers, State Relief Issues To Be Featured In House Hearings

Executive Summary

The House Energy & Commerce Committee is planning a series of hearings on the best ways to relieve struggling state Medicaid programs

The House Energy & Commerce Committee is planning a series of hearings on the best ways to relieve struggling state Medicaid programs.

The committee expects to hold its first Medicaid hearing within the next month, with others to follow throughout the year. Staff is gathering data on how states are running their Medicaid programs, including their use of waivers to fund pharmaceutical assistance.

The committee hopes the hearings will shed light on whether the waiver process is working as it was intended, given that some states now spend a significant portion of their Medicaid budgets on covering otherwise non-Medicaid eligible populations. A recent appellate court ruling striking down the "Healthy Maine" drug program focused on the waiver process (1 (Also see "Maine To Resubmit Medicaid Waiver To HHS After Court Strikes Plan Down" - Pink Sheet, 6 Jan, 2003.), p. 17).

Committee Republicans will be investigating whether there are ways other than waivers to provide states with greater flexibility in their drug assistance efforts.

With states clamoring for budgetary relief, the issues of the size of the federal contribution to the Medicaid program and whether the core benefit package should be restructured are also likely to surface.

Some committee Democrats are also said to be interested in changing how Medicaid rebates are calculated. A proposal to base the formula on average wholesale price, rather than average manufacturers price, is one possibility. The change was originally proposed in President Bush's FY 2003 budget (2 (Also see "CMS Proposes Medicaid Rebate Increase By Tying Formula To AWP, Not AMP" - Pink Sheet, 11 Feb, 2002.), p. 3).

The committee's work is not likely to have an immediate relief effect; some Energy & Commerce members are indicating a reluctance to spend more federal dollars on a state "bail out" before the hearings are complete. Legislation could move in May or June, possibly attached to a Medicare drug benefit.

In the short run, the states could get help from the Senate, where Sen. John Rockefeller (D-W.Va.) introduced a bill (S 138) to provide a one-time $20 bil. grant to help finance increases in Medicaid spending. The legislation is being co-sponsored by new Finance Committee Republican Sen. Gordon Smith (Ore.) (see 3 (Also see "Senate Medicare Rx Bill Will Be Shaped By Cmte. With Four New Members" - Pink Sheet, 13 Jan, 2003.) ).

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS041094

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel